SHAREHOLDERS ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Inotiv, Inc. - NOTV - Stock News Source

NEW YORK, NY / ACCESS CABLE / July 20, 2022 / Manhattan BioSolutions, Inc. announced today that it has entered into two commercial evaluation license agreements with the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH), to generate and validate new conjugated therapies of antibodies and drugs (ADC). using monoclonal antibodies developed by NCI. ADCs take advantage of the targeting ability of antibodies to deliver drugs to the tumor microenvironment or directly to cancer cells.

Under the first agreement, Manhattan BioSolutions obtained the proprietary monoclonal antibody discovered and validated by Drs. Ira Pastan, MD, Distinguished Investigator, Chief Emeritus of the Molecular Biology Laboratory and Mitchell Ho, PhD, Director of the Antibody Engineering Program and Deputy Chief of the Molecular Biology Laboratory at the NCI Cancer Research Center. This antibody targets a cell surface glycoprotein that is overexpressed in multiple types of cancer, including mesothelioma, lung, ovarian, and pancreatic cancer. Dr. Ira Pastan is recognized for his pioneering contributions in the fields of receptor biology, which led to the discovery of a new class of antibody drugs called recombinant immunotoxins. The targeted immunotoxin he developed to treat a deadly form of leukemia is now an approved drug marketed by Astra Zeneca under the name Lumoxiti.

Sponsored Content:

The second license agreement grants access rights to a novel monoclonal antibody targeting a mutationally activated and overexpressed cell surface receptor tyrosine kinase in a rare pediatric cancer as well as other solid tumors. This antibody was discovered by the team of Javed Khan, MD, MD, principal investigator and deputy chief of the genetics branch of the NCI Center for Cancer Research.

The partnerships allow Manhattan BioSolutions to further expand its preclinical portfolio of innovative biological agents for oncology applications. The antibodies discovered at NCI will be combined with proprietary immunostimulatory linker payloads invented by Dr. L. Nathan Tumey, a former Pfizer medical chemist who is currently an associate professor in the School of Pharmacy and Pharmaceutical Sciences at the University of Binghamton. . The current collaboration follows a previously announced collaborative research agreement and grant award with the lab of Dr. Dhaval Shah, a former Pfizer scientist, now an associate professor in the Department of Pharmaceutical Sciences at the University at Buffalo.

“The synergistic combination of actives and platforms enables the discovery of new drug classes designed to activate host innate microbial defense immunity in the tumor microenvironment,” said Dr. Borys Shor, CEO of Manhattan BioSolutions. “We have assembled a world-class team of drug discovery experts to develop next-generation ADCs: a trio of former Pfizer scientific leaders, including Drs. Dhaval Shah and Nathan Tumey, all with a proven track record of bringing transformative oncology drugs into clinical development.”

About Manhattan BioSolutions

Sponsored Content: is a veteran-owned e-commerce with over 40,000 items at great prices and always free shipping

Manhattan BioSolutions, Inc is a privately held biotechnology company focused on the development of biological immunotherapies that target microbial recognition and host defense pathways for the treatment of advanced cancers. The company has established partnerships with Stony Brook University, The University at Buffalo, Binghamton University, INSERM, EVQLV, and has received grants from the National Institutes of Health (NIH), the National Science Foundation (NSF), the New Jersey Commission on Science, Innovation and Technology (CSIT), the New York State Center for Biotechnology at Stony Brook University, and the University at Buffalo Center for Big Data and Health Sciences Advanced Technology (UBCAT). Learn more at

Contact for investor inquiries:
Jordana Lovett, PhD
Director of Investor Relations
(857) 600-1021
[email protected]

FONT: manhattan biosolutions, inc.

See source version at access Antibodies in New Oncology Programs ADC Antibody Drug Conjugates

Source link

Leave a Reply

Your email address will not be published.